ALNY · CIK 0001178670
What Alnylam Pharmaceuticals, Inc. told the SEC could break it.
Alnylam's disclosures pair a concentrated revenue base with an outsourced, externally exposed supply chain. It expects AMVUTTRA to keep accounting for a significant portion of net product revenues, so the business hinges on sustaining and growing that one product, while it relies on third-party contract manufacturers for all of its drug-product needs and on the limited number of CMOs worldwide with the expertise to make siRNA therapeutics. That manufacturing footprint, largely outside the U.S., runs into two trade-policy hazards it flags: proposed tariffs of 100% or more on pharmaceuticals made abroad, and the December 2025 BIOSECURE Act restricting U.S. dealings with certain Chinese biotech firms — some of which are its counterparties.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- proposed pharmaceutical tariffs (100%+ on products/components made outside U.S.)medium
The administration has announced plans to impose tariffs of 100% or more on pharmaceuticals manufactured outside the U.S., raising input/material costs and disrupting Alnylam's predominantly foreign-CMO supply chain.
“In addition, the administration has initiated or is considering imposing tariffs on certain foreign goods, and has announced plans to impose or increase tariffs of potentially 100% or more on pharmaceuticals, including pharmaceutical products and components manufactured outside of the U.S.”
- BIOSECURE Act (China biotech counterparty restrictions)medium
The BIOSECURE Act, enacted December 2025 in the FY2026 NDAA, restricts U.S. dealings with certain Chinese biotech firms; Alnylam does business with companies in China whose arrangements may need to change.
“We do business with companies in China and it is possible some of our contractual counterparties could be impacted by the legislation described above and alternative arrangements may need to be made.”
Other disclosures
- single-product revenue concentration (AMVUTTRA)medium
AMVUTTRA accounts for a significant portion of Alnylam's net product revenues, making the business dependent on sustaining and growing sales of that one product.
“We expect that sales of AMVUTTRA will continue to account for a significant portion of our net product revenues in future years. As a result, our business is dependent upon our ability to sustain and grow revenues from sales of AMVUTTRA.”
SEC filing →As of 2026
Supplier concentration
- third-party CMOs for siRNA drug product (limited number worldwide)medium
Alnylam relies on third-party CMOs for all of its drug product requirements and on a limited number of CMOs worldwide with the expertise to manufacture siRNA therapeutics, concentrating commercial supply.
“At the present time, we only have the capacity to manufacture limited quantities of clinical trial drug substance ourselves, and otherwise we continue to rely on third party CMOs to manufacture additional drug substance, and we rely on third party CMOs for all of our drug product requirements for clinical and commercial use. There are a limited number of CMOs worldwide with the expertise to manufacture our siRNA therapeutic products, and we currently rely on a limited number of CMOs in North America, Europe and Asia to manufacture our products and product candidates.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Roche (F. Hoffmann-La Roche)
“We recognized $ 300.0 million in net revenue from collaborations as the development milestone specifically relates to the transfer of the license to Roche which occurred on the Effective Date.”
Cited →“We expect our royalty revenue will increase in 2026, as compared to 2025, primarily due to the continued growth of royalties earned from global net sales of Leqvio by Novartis.”
Cited →
Its suppliers
“Under the terms of this license agreement, we are entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% - 2.33%”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch